ESR1 and breast carcinoma: In order to examine the prognostic impact of tumor stroma on survival outcome, we analyzed breast cancer specific recurrences according to pERK or SMAα in CAFs and focused on untreated, ERα-positive tumors in the randomized treatment trial in order to obtain true prognostic information without interference of links to treatment effects.